$ACOG

Opaleye Management Inc. purchased $7K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 1,161 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $5.73 on 2026-05-27.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published May 29, 2026, 11:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 11:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

The disclosure may slightly improve sentiment, but without new company fundamentals it is unlikely to materially reprice the stock on its own.

02

Market read

Treat as a low-conviction sentiment datapoint rather than a catalyst.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it also provides no rationale; the transaction size is relatively small versus typical microcap float/liquidity.

Relevance 6/10Novelty 6/10Timing: After-hours/next-session read-through from today’s Form 4 filing (filed May 29).

Background

The article is a direct SEC EDGAR Form 4 disclosure of a 10% owner’s open-market purchase.

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. (10% owner) filed an open-market purchase of 1,161 shares at $5.73 on May 27, 2026.

Expected impact

Likely limited near-term impact; any reaction should be muted unless follow-on buying or fundamentals change.

Evidence & confidence

This is an SEC Form 4 ownership-change disclosure with a small dollar amount and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (liquidity needs, diversification, or non-informational timing) and may not reflect near-term fundamentals.

Key entities

  • Alpha Cognition Inc.

    Subject of the Form 4 insider transaction; Opaleye Management Inc. is the 10% owner buying shares.

  • Opaleye Management Inc.

    Reporter of the open-market purchase disclosed in the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.